January 30, 2012
“DENVER–(BUSINESS WIRE)– Cannabis Science, Inc. (OTCBB:CBIS.OB) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to share new photographs from this cancer patient with severe squamous cell carcinoma. These pictures clearly show that this patient, with previously treatment-resistant tumors, continues to make obvious improvement. The tumors appear to be dying and then healing after treatment with cannabis-based extracts.”
“Cannabis Science, Inc., a pioneering US biotech company developing pharmaceutical cannabis products, is happy to report an additional, apparently successful, self-medicated cannabis treatment for a cancer patient.
This case is very graphic in nature. One of the patient’s physicians said it was the worst case of squamous cell carcinoma cancer he had ever seen, while another refused to continue tending to the patient.
While this patient’s self-administered treatment with cannabis extracts is still in progress, the results after just two weeks of treatment are dramatic. Some of the tumors have disappeared and others have significantly shrunk to a fraction of their original size. Simultaneously, the patient has had a significant decrease in pain, improved sleeping (the 1st full night of sleep in 3 years), as well as relief from the symptoms of multiple sclerosis that the patient also suffers from. This self-treatment is a work in progress.”
“Cell-based experiments or in vivo animal testing suggest that regulation of the endocannabinoid circuitry can impact almost every major function associated with the immune system. These studies were assisted by the development of numerous novel molecules that exert their biological effects through the endocannabinoid system. Several of these compounds were tested for their effects on immune function, and the results suggest therapeutic opportunities for a variety of inflammatory diseases such as multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, allergic asthma, and autoimmune diabetes through modulation of the endocannabinoid system.”
http://www.ingentaconnect.com/content/ben/ctmc/2006/00000006/00000013/art00008
A study out of the University of California shows that smoking marijuana can reduce the pain as well as muscle contractions and tightness of those living with multiple sclerosis.
Consuming plant cannabinoids leads to neurogenesis (birth of neurons), thanks to the endocannabinoid system.
“The endocannabinoid system exerts an important neuromodulatory function in different brain areas and is also known to be involved in the regulation of neural cell fate.
Thus, CB(1) cannabinoid receptors are neuroprotective in different models of brain injury, and their expression is altered in various neurodegenerative diseases. Recent findings have demonstrated the presence of a functional endocannabinoid system in neural progenitor cells that participates in the regulation of cell proliferation and differentiation.
In this Research Update, the authors address the experimental evidence regarding the regulatory role of cannabinoids in neurogenesis and analyze them in the context of those pathological disorders in which cannabinoid function and altered neuronal or glial generation is most relevant, for example, stroke and multiple sclerosis.”